Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Cancer Cell
|
January 9, 2026
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy
Andrea H Bild, Michelle C Sangar, Jasmine A McQuerry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2013
αB-crystallin: a novel regulator of breast cancer metastasis to the brain
Dmitry Malin, Elena Strekalova, Vladimir Petrovic, et al.
NAR Cancer
|
June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Kevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
Frederick M Howard, Anran Li, Sara Kochanny, et al.
JAMA Oncology
|
December 12, 2024
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
Ann H Partridge, Terry Hyslop, Shoshana M Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U Lin, Virginia Borges, Carey Anders, et al.
JAMA Oncology
|
February 17, 2017
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials
Ethan Basch, Amylou C Dueck, Lauren J Rogak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Cancer Cell
|
January 9, 2026
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy
Andrea H Bild, Michelle C Sangar, Jasmine A McQuerry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2013
αB-crystallin: a novel regulator of breast cancer metastasis to the brain
Dmitry Malin, Elena Strekalova, Vladimir Petrovic, et al.
NAR Cancer
|
June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Kevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
Frederick M Howard, Anran Li, Sara Kochanny, et al.
JAMA Oncology
|
December 12, 2024
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
Ann H Partridge, Terry Hyslop, Shoshana M Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U Lin, Virginia Borges, Carey Anders, et al.
JAMA Oncology
|
February 17, 2017
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials
Ethan Basch, Amylou C Dueck, Lauren J Rogak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Page
of 5